AstraZeneca: Beyfortus approved in China
Beyfortus is expected to be available during the upcoming RSV 2024-2025 season.
' As an innovative long-acting monoclonal antibody, Beyfortus can protect infants throughout the RSV season with a single dose. Its approval in China could potentially ease the burden of disease on children and their families, and alleviate pressure on the medical system due to pediatric respiratory diseases', commented Professor Liu Hanmin, President of the Second University Hospital of Western China, Sichuan University.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction